BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11062751)

  • 21. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer.
    Mancuso A; Giuliani R; Accettura C; Palma M; D'Auria G; Cecere F; Paoluzzi L; Bezzi M; Massidda B; Cortesi E
    Anticancer Res; 2003; 23(2C):1917-22. PubMed ID: 12820479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.
    Tonini G; Santini D; Vincenzi B; Borzomati D; Dicuonzo G; La Cesa A; Onori N; Coppola R
    J Biol Regul Homeost Agents; 2002; 16(2):105-9. PubMed ID: 12144121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
    Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
    Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
    Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
    Yamashita K; Urakami A; Kubota H; Nagatsuka R; Murakami H; Kawabe Y; Higashida M; Hirabayashi Y; Mikami Y; Ikeda M; Fuchimoto M; Yamamura M; Oka Y; Okumura H; Iki K; Matsumoto H; Imai S; Hirai T; Tsunoda T
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):71-6. PubMed ID: 18195531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
    Hasegawa S; Matsumoto S; Kawashima K; Fujii H; Hatano E; Satoh S; Ikai I; Shimahara Y
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):1045-9. PubMed ID: 16044971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy.
    Martin RC; Scoggins CR; McMasters KM
    J Surg Oncol; 2006 Apr; 93(5):387-93. PubMed ID: 16550574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases.
    Dizon DS; Schwartz J; Kemeny N
    Surg Oncol Clin N Am; 2008 Oct; 17(4):759-71, viii. PubMed ID: 18722916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
    Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
    Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: hepatic interstitial brachytherapy plus regional chemotherapy.
    Wieners G; Pech M; Hildebrandt B; Peters N; Nicolaou A; Mohnike K; Seidensticker M; Sawicki M; Wust P; Ricke J
    Cardiovasc Intervent Radiol; 2009 Sep; 32(5):937-45. PubMed ID: 19472000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
    Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
    Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.
    van Iersel LB; Koudijs TM; Hoekman EJ; Janssen-van Rhijn CM; Vahrmeijer AL; Nortier JW; van de Velde CJ; Gelderblom H; Kuppen PJ
    J Surg Res; 2011 May; 167(2):273-8. PubMed ID: 20036390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
    Kim JC; Kim HC; Lee KH; Yu CS; Kim TW; Chang HM; Ryu MH; Kim JH; Ha HK; Lee MG
    J Gastroenterol Hepatol; 2006 Jun; 21(6):1026-35. PubMed ID: 16724990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
    Pilati P; Mammano E; Mocellin S; Tessari E; Lise M; Nitti D
    Anticancer Res; 2009 Oct; 29(10):4139-44. PubMed ID: 19846962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
    Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
    Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
    Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
    Flis S; Gnyszka A; Spławiński J
    Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
    Benoist S; Nordlinger B
    Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.